Amgen's first quarter revenues and earnings per share beat analyst expectations, reaching $5.6 billion and $3.25 respectively on higher product sales, the company reported April 24. In particular, the Thousand Oaks biotech giant’s cholesterol drug Repatha saw a 151 percent increase in sales after receiving U.S. Food and Drug Administration approval in December to be…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
